VEGFA and renal cell carcinoma: Treatment is typically modeled after the most closely resembling RCC subtype: VEGF or mesenchymal-epithelial transition (MET) inhibitors may be considered for papillary-like morphology, while TKI- or immunotherapy-based regimens are used for clear-cell-like or high-grade tumors [124].